Press Releases
Biolex Presents Phase 2B Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated with Locteron®
March 31, 2011
Poster Presented at EASL
Biolex Presents Final Phase 2B Results at EASL Highlighting Tolerability Advantages of Locteron® in Treatment of HCV
March 31, 2011
Poster Presented at EASL
Biolex to Present Final Phase 2B Results at EASL for Locteron® Next-Generation Controlled-Release Interferon for HCV
March 10, 2011
Biolex Therapeutics Names Kurt Graves Executive Chairman as Company Prepares for Phase 3 Trials and Commercialization of Locteron® in
Hepatitis C
November 9, 2010
Biolex Presents at AASLD Meeting Significant Tolerability Advantages of Locteron®, Its Next-Generation Interferon for Hepatitis C
-Locteron Phase 2b Results Include Statistically Significant Reduction of Flu-Like Adverse Events Confirmed by Two Independent Reporting Methods
November 1, 2010
Biolex Announces Locteron® SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial
-Additional Tolerability Results from Two Phase 2b Trials of Locteron to be Presented in Late-Breaker Session at AASLD Conference on November 1, 2010
October 28, 2010
Biolex and Merial Broaden Collaboration
-Innovative Vaccines from a Novel Antigen Expression and Manufacturing Platform
July 15, 2010
Biolex Announces Presentation at EASL of Interim Results from 480 Study, a Phase 2b Trial of Locteron® in Chronic Hepatitis C
April 19, 2010
Biolex Announces Presentation at EASL of Interim Results from EMPOWER Phase 2b Study of Locteron® in Chronic Hepatitis C
-Locteron dosed once every two weeks demonstrated a comparable reduction in viral load compared to once-weekly standard of care with 57% less flu-like adverse events
April 16, 2010
Biolex Announces Presentation at EASL of Interim Results from SELECT-2 Phase 2b Trial of Locteron® in Chronic Hepatitis C
-Locteron dosed once-every-two-weeks demonstrated a comparable reduction in viral load compared to once-weekly standard of care with a 65% reduction in flu-like adverse events
April 15, 2010
Biolex Announces Locteron® Phase 2b Interim Results in Hepatitis C Accepted for Presentation at EASL Conference
February 10, 2010
Biolex Therapeutics Selects
Cook Pharmica as Contract Manufacturer of Locteron® Drug Substance for Phase 3 Trials
August 27, 2009
Biolex Announces Oral Presentation of Preclinical Results for Direct-Acting Thrombolytic BLX-155 at ISTH Meeting
-Preclinical Results Show Superior Thrombolytic Activity for BLX-155 Compared to t-PA
July 16, 2009
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2B Trial of Locteron® in Chronic Hepatitis C
June 29, 2009
Biolex Therapeutics Researchers Present Locteron® U.S. Phase 2a Hepatitis C Trial Results at EASL Conference
April 24, 2009
Biolex Therapeutics Commences Phase 2B Trial of Locteron® in Chronic Hepatitis C
April 20, 2009
Biolex Therapeutics Adds Two Drug Development Executives to Accelerate Development of Locteron® in Hepatitis C
-Bipin Dalmia, Ph.D., MBA Promoted to Senior Vice President-
November 3, 2008
Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C
-Financing Led by Clarus Ventures-
October 6, 2008
Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron® Commercial Rights
October 6, 2008
Biolex Therapeutics Adds $10.5 Million in Growth Capital
July 28, 2008
MRC Technology and Biolex Therapeutics Successfully Complete Collaboration to Humanize a Novel Antibody Targeting CD20
July 14, 2008
Biolex Therapeutics Researchers Present Locteron® Phase 2a Hepatitis C Trial Results at EASL Conference
April 24, 2008
Biolex Announces Presentation of Preclinical Results for Clot Buster
BLX-155 at SIR Annual Scientific Meeting
March 18, 2008
Biolex Announces Publication of Phase 1 Locteron® Results in the Journal of Interferon & Cytokine Research
March 12, 2008
Biolex Therapeutics Enters into Agreement with Merck KGaA for Antibody Optimization
February 19, 2008
Biolex Therapeutics Commences United States Phase 2a Trial of Locteron® in Hepatitis C
February 7, 2008
Biolex Researchers Present Results of Anti-CD20 Antibody with Optimized Glycosylation at ASH Conference
-Preclinical Results Demonstrate Potential for Improved Efficacy and Potency and Reduced Side Effects Compared to Rituxan®-
December 10, 2007
Biolex Therapeutics Researchers Present Locteron™ Phase 2a Hepatitis C Trial Results at AASLD Conference
-Phase 2a Trial Demonstrates Statistically Significant Dose Response-
November 6, 2007
Biolex Therapeutics' Locteron™ Phase 2a Hepatitis C Trial Results Selected for Presentation at AASLD Conference
-Biolex Also Announces Top-Line Data from Complete Phase 2a Trial Highlighting Favorable Viral Response and Tolerability Results-
October 12, 2007
Biolex Files for Initial Public Offering
August 14, 2007
Biolex Therapeutics Announces Positive Phase 2a Results for Hepatitis C Product Candidate Locteron™
July 26, 2007
Biolex Therapeutics Presents Preclinical Results for Clot Buster BLX-155 at the International Society on Thrombosis and Haemostasis Meeting
-Clinical Development Program for BLX-155 Also Announced-
July 13, 2007
Biolex Therapeutics Raises $30 Million to Advance Its Hepatitis C Drug Candidate and Other Pipeline Programs
May 24, 2007
Biolex Therapeutics Announces Agreement with Genmab for New Class of Antibodies
May 7, 2007
Biolex Therapeutics' Lex SystemSM Featured in Breakout Session at the 2007 BIO International Convention
May 3, 2007
Biolex Therapeutics Announces Strategic Collaboration with Merial
for Animal Health Vaccines
-Collaboration encompasses first vaccines to be produced with LEX SystemSM
May 1, 2007
Biolex Therapeutics to Present at the BioCentury and Thomson Financial "Future Leaders in the Biotech Industry" Conference
March 26, 2007
Biolex Therapeutics Researchers Present Preclinical Data for Direct-Acting Thrombolytic BLX-155 at Scientific Conference
-First Protein Expression System to Produce Commercially Viable Levels of Full-Length Recombinant Plasmin-
March 1, 2007
Biolex Therapeutics Featured at Next Generation Antibody Panel at BIO CEO & Investor Conference
February 13, 2007
Biolex Therapeutics Announces Initiation of Locteron™ Phase 2 Clinical Study in Chronic Hepatitis C
January 30, 2007
Biolex Therapeutics to Present at the 25th Annual JPMorgan Healthcare Conference
January 4, 2007
Biolex Announces Publication in Nature Biotechnology Demonstrating Potential to Produce Monoclonal Antibodies with Increased Potency and Efficacy
November 28, 2006
Biolex Therapeutics Honored By NCTA As Top Venture Company Of The Year
November 15, 2006
Biolex Therapeutics Featured at the 9th Annual Facilities For Mammalian Cell Product Conference
-Conference Attendees Tour Biolex’ Award-Winning GMP Biomanufacturing Facility-
October 18, 2006
Biolex Therapeutics Announces Positive Phase 1 Results for Hepatitis C Product Candidate Locteron™
April 27, 2006
Biolex Therapeutics Announces Expansion Of Medarex Collaboration
- Agreement Expanded To Include Three Medarex Monoclonal Antibodies-
April 11, 2006
Biolex Therapeutics Receives Prestigious Award for Manufacturing Facility
March 22, 2006
Biolex Therapeutics Presents Results Highlighting Benefits of Locteron™ at "Breakthroughs in Hepatitis" Session
February 15, 2006
Biolex Therapeutics Announces Recruitment of Three Key Management Team Additions to Accelerate Commercialization of Lead Programs
November 16, 2005
Biolex Therapeutics Announces Initiation of Phase 1 Clinical Study of Hepatitis C Candidate Locteron™
November 2, 2005
Biolex Therapeutics and Kringle Pharma Announce Collaboration For Production of a Novel Protein Targeting Cancer
October 27, 2005
Biolex Therapeutics Successfully Completes Phase 1 Study For First Lex System ™ Produced Therapeutic Protein
October 26, 2005
Biolex Therapeutics Doubles Manufacturing Capacity, Realizing Significant Economic and Time Efficiencies
Capabilities in Place for Partners and Biolex Proteins
September 13, 2005
Biolex Therapeutics Raises $36 Million in Venture Financing
September 1, 2005
Biolex Therapeutics Acquires LemnaGene S.A. -- Further Consolidates Protein Capabilities
July 28, 2005
Biolex Announces Broad Patent Covering Treatment of Humans with Plant-Made Antibodies
Patent Further Strengthens Biolex' Plantibodies™ IP Portfolio
March 31, 2005
Biolex Forms Broad Strategic Alliance With Centocor to Develop and Manufacture Therapeutic Proteins
Alliance to Include Up to Ten Proteins
March 21, 2005
Biolex and Octoplus Announce Joint Development of Locteron™: A Novel, Controlled Release Formulation of Alfa Interferon
Clinical Trials to Commence in 2005
February 16, 2005
Dale A. Sander Joins Biolex As Chief Financial Officer and Senior Vice President
February 9, 2005
Biolex and Medarex Sign Research Collaboration Agreement
Eleventh Partner Protein to Begin Commercial Line Creation Using LEX System™
February 4, 2005
Biolex Submits IND and CTA for BLX-883, A Form of Alfa Interferon Manufactured with the Biolex LEX System™
January 6, 2005
Biolex Announces the Further Expansion of Its Collaboration with Centocor
October 6, 2004
Biolex Celebrates Opening of Its New cGMP Biopharmaceutical Manufacturing Facility
September 27, 2004
Biolex Expands Board of Directors and Promotes Key Management
August 31, 2004
Biolex Receives CED's 2004 Deal of the Year Award
June 17, 2004
Biolex Advances Development of a Centocor Therapeutic Protein Candidate
June 4, 2004
Biolex Acquires Epicyte Pharmaceutical
May 6, 2004
NCEITA Honors Biolex as the 2003 Top Venture Firm Invested Company of the Year
November 26, 2003
Dr. Bipin K. Dalmia Joins Biolex, Inc. As Vice President, Business Development
September 22, 2003
Biolex Raises Over $24 Million In Venture Capital Financing
August 20, 2003
Biolex, Inc. Announces Formation Of Blue Ribbon Development Advisory Board
July 14, 2003
Biolex, Inc. Signs Research Collaboration With Centocor On Multiple Proteins
June 22, 2003
Biolex, Inc. and Bayer Corporation Sign Research Collaboration Agreement
October 3, 2002
Biolex, Inc. and Debiopharm S.A. Sign Collaboration
September 12, 2002
John A. Irick Joins Biolex, Inc. As Senior Vice President, Corporate And Business Development
January 9, 2002
Biolex, Inc. Announces Appointment Of New Vice President Of Research And Development And Chief Operating Officer
October 29, 2001
New President and CEO Joins Biolex, Inc.
July 12, 2001
Return to top
|
